J
Joell J. Gills
Researcher at Johns Hopkins University School of Medicine
Publications - 43
Citations - 3356
Joell J. Gills is an academic researcher from Johns Hopkins University School of Medicine. The author has contributed to research in topics: Protein kinase B & Cancer. The author has an hindex of 25, co-authored 41 publications receiving 2992 citations. Previous affiliations of Joell J. Gills include University of Illinois at Chicago & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Control of PD-L1 Expression by Oncogenic Activation of the AKT–mTOR Pathway in Non–Small Cell Lung Cancer
Kristin J. Lastwika,Kristin J. Lastwika,Willie Wilson,Qing Kay Li,Jeffrey William Norris,Haiying Xu,Sharon R. Ghazarian,Hiroshi Kitagawa,Shigeru Kawabata,Janis M. Taube,Sheng Yao,Linda N. Liu,Joell J. Gills,Phillip A. Dennis +13 more
TL;DR: It is suggested that oncogenic activation of the AKT-mTOR pathway promotes immune escape by driving expression of PD-L1, which was confirmed in syngeneic and genetically engineered mouse models of lung cancer where an mTOR inhibitor combined with a PD-1 antibody decreased tumor growth, increased tumor-infiltrating T cells, and decreased regulatory T cells.
Journal ArticleDOI
Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo.
Joell J. Gills,Jaclyn LoPiccolo,Junji Tsurutani,Robert H. Shoemaker,Carolyn J.M. Best,Mones Abu-Asab,Jennifer P. Borojerdi,Noel A. Warfel,Erin R. Gardner,Matthew Danish,M. Christine Hollander,Shigeru Kawabata,Maria Tsokos,William D. Figg,Patricia S. Steeg,Phillip A. Dennis +15 more
TL;DR: Nelfinavir is a lead HIV protease inhibitor with pleiotropic effects in cancer cells and is a Food and Drug Administration–approved drug that could be repositioned as a cancer therapeutic.
Journal ArticleDOI
Tobacco components stimulate Akt-dependent proliferation and NFκB-dependent survival in lung cancer cells
Junji Tsurutani,S. Sianna Castillo,John Brognard,Courtney A. Granville,Chunyu Zhang,Joell J. Gills,Jacqueline Sayyah,Phillip A. Dennis +7 more
TL;DR: Results identify tobacco component-induced, Akt-dependent proliferation and NFkappaB-dependent survival as cellular processes that could underlie the detrimental effects of smoking in cancer patients.
Journal ArticleDOI
Repositioning metformin for cancer prevention and treatment.
TL;DR: Improved understanding of these issues will increase the chances for successful application of metformin as an inexpensive, well-tolerated, and effective anticancer agent.
Journal ArticleDOI
Perifosine: Update on a novel Akt inhibitor
Joell J. Gills,Phillip A. Dennis +1 more
TL;DR: The clinical history of perifosine is reviewed and its many biologic activities are discussed, including its role in Akt inhibition, which is a nodal regulator of cellular survival pathways and an attractive target in cancer therapy.